McCoy Lucie, Sorvillo Frank, Simon Paul
Los Angeles County Department of Health Services, Los Angeles, CA, USA.
Pediatr Infect Dis J. 2004 Jun;23(6):498-503. doi: 10.1097/01.inf.0000129684.27717.d6.
Although surveillance for varicella in the United States has documented a reduction in cases since vaccine licensure in 1995, information is lacking on varicella-related mortality since vaccine introduction. This study identifies varicella-related mortality in California before and after vaccine introduction and assesses how high risk conditions and complications contributed to varicella deaths during this period.
California death records mentioning varicella as either an underlying or contributing cause of death were selected from the 1988-2000 multiple cause-of-death files. Pre- and postvaccine periods were compared to assess differences in varicella mortality before and after vaccine introduction. Differences in varicella mortality by age, race/ethnicity and gender were also examined. ICD codes were used to identify high risk conditions and varicella-related complications.
A total of 228 varicella-related deaths were reported between 1988 and 2000 in California. Age-adjusted varicella mortality rates showed a downward trend during this period, dropping from a high of 0.97 per million in 1990 to a low of 0.22 per million in 1999. The average age-adjusted mortality rate declined from 0.67 per million prevaccine to 0.38 per million postvaccine. Compared with the prevaccine period, the average rate of decline in varicella mortality was greater after vaccine implementation. Infants had the highest mortality rate for the period. At least one immunocompromising condition was present in 38% of varicella-related deaths. Pneumonia was the most commonly reported complication.
Varicella-related mortality declined in California after vaccine implementation, but potentially preventable varicella-related deaths continue to occur.
尽管美国对水痘的监测记录显示自1995年疫苗获得许可以来病例有所减少,但自疫苗引入后水痘相关死亡率的信息却很缺乏。本研究确定了疫苗引入前后加利福尼亚州水痘相关死亡率,并评估了在此期间高危状况和并发症对水痘死亡的影响。
从1988 - 2000年多死因档案中选取提及水痘为根本死因或促成死因的加利福尼亚州死亡记录。比较疫苗接种前后时期,以评估疫苗引入前后水痘死亡率的差异。还研究了按年龄、种族/族裔和性别划分的水痘死亡率差异。使用国际疾病分类代码识别高危状况和水痘相关并发症。
1988年至2000年期间,加利福尼亚州共报告了228例水痘相关死亡。年龄调整后的水痘死亡率在此期间呈下降趋势,从1990年的每百万0.97降至1999年的每百万0.22的低点。平均年龄调整死亡率从前疫苗时期的每百万0.67降至后疫苗时期的每百万0.38。与疫苗接种前时期相比,疫苗实施后水痘死亡率的平均下降速度更快。婴儿在此期间死亡率最高。38%的水痘相关死亡病例存在至少一种免疫功能低下状况。肺炎是最常报告的并发症。
疫苗实施后,加利福尼亚州水痘相关死亡率下降,但仍有潜在可预防的水痘相关死亡继续发生。